Low-grade follicular lymphomas: Analysis of prognosis in a series of 281 patients

Soubeyran, Pierre; Eghbali, Houchingue; Bonichon, F.; Trojani, M; Richaud, Pierre; Hoerni, B

doi:10.1016/0277-5379(91)90425-d

Cited by 55 publications

(11 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…(It was not possible to assess the influence of a high LDH level, since LDH was not routinely measured at the time that this study began.) Older age was the only factor that correlated significantly with worse survival, in agreement with most previous analyses (Rudders et al, 1979;Gospodarowicz et al, 1984;Kantarjian et al, 1984;Gallagher et al, 1986;Lawrence et al, 1988;Steward et al, 1988;Lepage et al, 1990;Leonard et al, 1991;Romaguera et al, 1991;Soubeyran et al, 1991).…”

Section: Discussionsupporting

confidence: 91%

A randomized controlled trial to evaluate the role of interferon as initial and maintenance therapy in patients with follicular lymphoma

et al. 2001

View full text Add to dashboard Cite

The purpose of this study was to evaluate the role of interferon as initial and maintenance therapy in patients with newly diagnosed follicular lymphoma. Between 1984 and 1994, 204 patients with newly diagnosed Stage III or Stage IV follicular lymphoma were randomized to receive either, Chlorambucil (CB): 10 mg daily for 6 weeks, followed by a 2-week interval, with 3 subsequent 2-week treatment periods at the same dose, separated by 2-week intervals, or, CB given concurrently with interferon (IFN). IFN was given at a dose of 3 × 10 6 units thrice weekly, subcutaneously, throughout the 18-week treatment period. Responding patients were subsequently randomized to receive maintenance IFN at the dose and schedule described above, or to expectant management. The overall response rate was 161/204 (78%), complete remission being achieved in 24% of patients. Neither the addition of IFN to the initial treatment, nor the use of maintenance IFN influenced response rate, remission duration or survival. This study was undertaken to determine whether IFN, given in combination with, and then subsequent to, CB would alter the clinical course of patients with follicular lymphoma. Disappointingly, this objective was not achieved, no advantage having been demonstrated for the addition of IFN. © 2001 Cancer Research Campaign http://www.bjcancer.com

show abstract

Section: Discussionsupporting

confidence: 91%

A randomized controlled trial to evaluate the role of interferon as initial and maintenance therapy in patients with follicular lymphoma

et al. 2001

View full text Add to dashboard Cite

show abstract

“…All the parameters of the FLIPI have been found to significantly influence prognosis in several other analyses [3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20] and have been included For personal use only. on May 11, 2018.…”

Section: Discussionmentioning

confidence: 99%

“…Agreement in the treatment algorithm of patients with FL would be made easier by a simple, validated, and accurate prognostic index similar to the International Prognostic Index proposed for aggressive NHLs in 1993. 2 In retrospective analyses of a series of FL or indolent NHLs, several characteristics were associated with a poor clinical outcome such as advanced age, [3][4][5][6][7][8][9][10] male sex, 4,7,11,12 disseminated disease according to Ann Arbor classification, 1,4 high number of nodal 3,7 and/or extra nodal involvement sites, 12 presence of bulky tumor(s), 6,8 increased serum lactate dehydrogenase (LDH) 13 and/or ␤ 2 microglobulin 14 levels, poor performance status, 5,6 and a low hemoglobin level. 4 From these analyses, a few prognostic indices have been proposed 3,4,9,12 but none of them has been validated and/or widely used.…”

Section: Introductionmentioning

confidence: 99%

Follicular Lymphoma International Prognostic Index

Solal-Céligny¹

2004

Blood

1,516

695

View full text Add to dashboard Cite

“…This relationship between down-regulation of bcl-2/IgH expression and outcome was expected because of the correlation observed with response that is already known to have important prognostic value (Soubeyran et al, 1991). However, this is another argument for the potential value of bcl-2/IgH expression downregulation in FL.…”

Section: Discussionmentioning

confidence: 78%

“…Localized stages were treated by involved field irradiation either alone or combined with induction chemotherapy (CVP regimen) (Soubeyran et al, 1988), or lowdose total body irradiation as part of a prospective phase II trial (Richaud et al, 1998). After an eventual wait-and-see period, advanced stages were treated with different chemotherapies (Chauvergne et al, 1977;Bonadonna et al, 1985;Soubeyran et al, 1991) including continuous oral treatment with cyclophosphamide (100 mg per day) or chlorambucil (4 mg per day), CVP (cyclophosphamide 750 mg m -2 day 1, vincristine 1.4 mg m -2 day 1, prednisone 40 mg m -2 days 1-7), fludarabine (25 mg m -2 days 1-5), CEP (carmustine 100 mg m -2 day 1, etoposide 100 mg m -2 days 1-5, prednimustine 80 mg m -2 days 1-5) or teniposide (100 mg m -2 weekly). One patient received anti-CD52 monoclonal antibody therapy as part of a phase II study.…”

Section: Patientsmentioning

confidence: 99%

Evolution of BCL-2/IgH hybrid gene RNA expression during treatment of T(14;18)-bearing follicular lymphomas

Soubeyran¹,

Hostein²,

Debled³

et al. 1999

Br J Cancer

View full text Add to dashboard Cite

Bcl-2, the gene over-expressed in follicular lymphomas (FL), is able to block chemotherapy-induced apoptosis. Consequently, we wondered whether bcl-2/IgH expression variations during treatment of FL could predict the outcome of patients with t(14;18)-bearing FL. For this purpose, we used a reverse transcription polymerase chain reaction (RT-PCR) assay to analyse 180 serial peripheral blood samples (PBS) during 34 treatment phases in 25 patients with t(14;18)-bearing FL. In all patients but two, bcl-2/IgH gene expression was demonstrated in pre-treatment samples. During 16 out of the 34 treatment phases (47%), bcl-2/IgH expression became negative: all but one were responders to chemotherapy. This conversion was transient in six cases. In 18 treatment phases, bcl2/IgH expression remained detectable: eight were clinically considered as treatment failures, while eight others achieved PR and two achieved CR. We observed a significant correlation between treatment response and RNA PCR results ( P = 0.002). Three-year overall survival of patients with stable bcl2/IgH-negative conversion was 100% compared to 54% for the remaining patients ( P = 0.069); 3-year freedom from progression was respectively 87.5% and 13% ( P = 0.005). These results indicate a correlation between bcl-2/IgH expression variations and both clinical response and outcome. Whether this might predict disease outcome early remains to be confirmed. © 1999 Cancer Research Campaign

show abstract

Low-grade follicular lymphomas: Analysis of prognosis in a series of 281 patients

Cited by 55 publications

References 21 publications

A randomized controlled trial to evaluate the role of interferon as initial and maintenance therapy in patients with follicular lymphoma

A randomized controlled trial to evaluate the role of interferon as initial and maintenance therapy in patients with follicular lymphoma

Follicular Lymphoma International Prognostic Index

Evolution of BCL-2/IgH hybrid gene RNA expression during treatment of T(14;18)-bearing follicular lymphomas

Contact Info

Product

Resources

About